Oesophageal squamous cell carcinoma (ESCC): Advances through omics technologies, towards ESCC salivaomics

Juan J osé González-Plaza, Nataša Hulak, Eduardo García-Fuentes, Lourdes Garrido-Sánchez, Zhaxybay Zhumadilov, Ainur Akilzhanova

Research output: Contribution to journalReview articlepeer-review


Oesophageal Squamous Cell Carcinoma (ESCC) is one of the two main subtypes of oesophageal cancer, affecting mainly populations in Asia. Though there have been great efforts to develop methods for a better prognosis, there is still a limitation in the staging of this affection. As a result, ESCC is detected at advances stages, when the interventions on the patient do not have such a positive outcome, leading in many cases to recurrence and to a very low 5-year survival rate, causing high mortality. A way to decrease the number of deaths is the use of biomarkers that can trace the advance of the disease at early stages, when surgical or chemotherapeutic methodologies would have a greater effect on the evolution of the subject. The new high throughput omics technologies offer an unprecedented chance to screen for thousands of molecules at the same time, from which a new set of biomarkers could be developed. One of the most convenient types of samples is saliva, an accessible body fluid that has the advantage of being non-invasive for the patient, being easy to store or to process. This review will focus on the current status of the new omics technologies regarding salivaomics in ESCC, or when not evaluated yet, the achievements in related diseases.

Original languageEnglish
Pages (from-to)247-257
Number of pages11
JournalDrug Discoveries and Therapeutics
Issue number4
Publication statusPublished - Aug 1 2015

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Oesophageal squamous cell carcinoma (ESCC): Advances through omics technologies, towards ESCC salivaomics'. Together they form a unique fingerprint.

Cite this